Presence of Smartphone Cuts Available Cognitive Capacity

This article originally appeared here.
Share this content:
Presence of Smartphone Cuts Available Cognitive Capacity
Presence of Smartphone Cuts Available Cognitive Capacity

WEDNESDAY, June 28, 2017 (HealthDay News) -- Just the presence of one's smartphone is associated with reduced available cognitive capacity, according to a study published recently in the Journal of the Association for Consumer Research.

Noting that smartphones have immense potential to improve welfare, Adrian F. Ward, Ph.D., from the University of Texas at Austin, and colleagues examined the cognitive impact of smartphones. They tested the "brain-drain" hypothesis: that the presence of one's smartphone occupies limited-capacity cognitive resources, thereby undercutting cognitive performance.

Based on results of two experiments, the researchers found that even when people were successful at maintaining sustained attention by avoiding the temptation to check their phones, the presence of the devices was associated with a reduction in cognitive capacity. These cognitive costs were highest for those with the highest dependence on smartphones. This smartphone-induced brain drain can have practical implications for decision-making and consumer welfare.

"Our data suggest that the mere presence of consumers' own smartphones may further constrain their already limited cognitive capacity by taxing the attentional resources that reside at the core of both working memory capacity and fluid intelligence," the authors write. "Because consumers' smartphones are so frequently present, the mere presence effects observed in our experiments have the potential to influence consumer welfare across a wide range of contexts."

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths